ASCENTAGE PHARMA GROUP-B (06855) announced that, as of the date of this announcement, it has granted 1.3045 million restricted share units under the 2022 Restricted Share Unit Plan to 146 selected participants, equivalent to 1.3045 million shares (2022 Further Grant). Additionally, the company has issued a total of 736,600 share options to 34 grantees under the terms of the Post-IPO Share Option Scheme, allowing the subscription of an equivalent number of ordinary shares, subject to acceptance by the option holders.